Filipa Raposo Pereira1,2, Minni T B McMaster3,4, Yvon D A T de Vries3, Nikki Polderman3, Wim van den Brink3,4, Guido A van Wingen3,4. 1. Department of Psychiatry, Amsterdam Neuroscience, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands, f.raposopereira@amc.uva.nl. 2. Amsterdam Brain and Cognition, University of Amsterdam, Amsterdam, The Netherlands, f.raposopereira@amc.uva.nl. 3. Department of Psychiatry, Amsterdam Neuroscience, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. 4. Amsterdam Brain and Cognition, University of Amsterdam, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Gamma-hydroxybutyric acid (GHB) is a drug of abuse associated with increased emergency room attendances, due to GHB-induced comas. Withdrawal from GHB often increases social anxiety and is linked to alterations in emotion processing. However, little is known about the effects of GHB-use and GHB-induced comas on affect regulation in humans. OBJECTIVES: We aimed to assess the effect of GHB-use and GHB-induced comas on the affective network. METHOD: We recruited 27 GHB users with ≥4 GHB-induced comas (GHB-Coma), 27 GHB users without a GHB-induced coma (GHB-NoComa), and 27 polydrug users who never used GHB (No-GHB). Participants completed self-report questionnaires assessing negative affect (depression, anxiety and stress) and performed an emotional face matching task during functional magnetic resonance imaging to probe activity of the amygdala and the hippocampus. RESULTS: The GHB-Coma group reported higher levels of depression, anxiety, and stress; showed decreased activity of the hippocampus; and increased functional connectivity of the left hippocampus with the left fusiform gyrus and a cluster on the left temporal-parietal-occipital junction, when compared with the 2 other groups. The GHB-NoComa group showed decreased functional connectivity of the left hippocampus with the amygdala in comparison with the No-GHB group. CONCLUSIONS: GHB-use but in particular GHB-induced comas, are associated with altered emotion identification and hippocampal functioning. Awareness campaigns are required to raise consciousness about the adverse effects of GHB-induced comas on affect regulation, despite the absence of subjective side effects.
BACKGROUND:Gamma-hydroxybutyric acid (GHB) is a drug of abuse associated with increased emergency room attendances, due to GHB-induced comas. Withdrawal from GHB often increases social anxiety and is linked to alterations in emotion processing. However, little is known about the effects of GHB-use and GHB-induced comas on affect regulation in humans. OBJECTIVES: We aimed to assess the effect of GHB-use and GHB-induced comas on the affective network. METHOD: We recruited 27 GHB users with ≥4 GHB-induced comas (GHB-Coma), 27 GHB users without a GHB-induced coma (GHB-NoComa), and 27 polydrug users who never used GHB (No-GHB). Participants completed self-report questionnaires assessing negative affect (depression, anxiety and stress) and performed an emotional face matching task during functional magnetic resonance imaging to probe activity of the amygdala and the hippocampus. RESULTS: The GHB-Coma group reported higher levels of depression, anxiety, and stress; showed decreased activity of the hippocampus; and increased functional connectivity of the left hippocampus with the left fusiform gyrus and a cluster on the left temporal-parietal-occipital junction, when compared with the 2 other groups. The GHB-NoComa group showed decreased functional connectivity of the left hippocampus with the amygdala in comparison with the No-GHB group. CONCLUSIONS:GHB-use but in particular GHB-induced comas, are associated with altered emotion identification and hippocampal functioning. Awareness campaigns are required to raise consciousness about the adverse effects of GHB-induced comas on affect regulation, despite the absence of subjective side effects.
Authors: Petra S van Nieuwenhuijzen; Leonora E Long; Glenn E Hunt; Jonathon C Arnold; Iain S McGregor Journal: Psychopharmacology (Berl) Date: 2010-08-21 Impact factor: 4.530
Authors: Oliver G Bosch; Michael M Havranek; Andrea Baumberger; Katrin H Preller; Robin von Rotz; Marcus Herdener; Rainer Kraehenmann; Philipp Staempfli; Milan Scheidegger; Tim Klucken; Erich Seifritz; Boris B Quednow Journal: Eur Neuropsychopharmacol Date: 2017-03-08 Impact factor: 4.600
Authors: Filipa Raposo Pereira; Minni T B McMaster; Nikki Polderman; Yvon D A T de Vries; Wim van den Brink; Guido A van Wingen Journal: Drug Alcohol Depend Date: 2018-06-26 Impact factor: 4.492
Authors: Filipa Raposo Pereira; Minni T B McMaster; Nikki Polderman; Yvon D A T de Vries; Wim van den Brink; Guido A van Wingen Journal: Neuroimage Clin Date: 2018-09-26 Impact factor: 4.881
Authors: Filipa Raposo Pereira; Minni T B McMaster; Arnt Schellekens; Nikki Polderman; Yvon D A T de Vries; Wim van den Brink; Guido A van Wingen Journal: Front Psychiatry Date: 2020-04-02 Impact factor: 4.157